每經AI快訊，日(ri)前，東(dong)北制(zhi)(zhi)藥(yao)公(gong)(gong)告，公(gong)(gong)司(si)(si)于今年(nian)8月宣布擬(ni)收購北京鼎(ding)成(cheng)肽源(yuan)生(sheng)物技(ji)術有限公(gong)(gong)司(si)(si)（簡稱“鼎(ding)成(cheng)肽源(yuan)”）70%的(de)(de)股(gu)權，鼎(ding)成(cheng)肽源(yuan)日(ri)前已(yi)辦理完成(cheng)股(gu)權變(bian)更的(de)(de)相(xiang)關備案核準手續(xu)。至此，鼎(ding)成(cheng)肽源(yuan)成(cheng)為(wei)公(gong)(gong)司(si)(si)的(de)(de)控股(gu)子公(gong)(gong)司(si)(si)并(bing)(bing)(bing)納入公(gong)(gong)司(si)(si)合并(bing)(bing)(bing)報表(biao)(biao)范圍。 近期，生(sheng)物醫藥(yao)行(xing)業(ye)(ye)并(bing)(bing)(bing)購活躍。10月以來，康緣藥(yao)業(ye)(ye)、千紅制(zhi)(zhi)藥(yao)、新諾威等多家生(sheng)物醫藥(yao)領域上(shang)市公(gong)(gong)司(si)(si)披(pi)露(lu)并(bing)(bing)(bing)購重(zhong)(zhong)組相(xiang)關事宜。業(ye)(ye)內(nei)人(ren)士表(biao)(biao)示，當前資產重(zhong)(zhong)組政策支持(chi)力度不斷增強，國(guo)內(nei)生(sheng)物醫藥(yao)行(xing)業(ye)(ye)有望掀(xian)起并(bing)(bing)(bing)購重(zhong)(zhong)組浪潮，并(bing)(bing)(bing)購驅(qu)動成(cheng)長將成(cheng)為(wei)未(wei)來重(zhong)(zhong)要主(zhu)線之(zhi)一(yi)。隨(sui)著政策對“兩創(chuang)”板塊公(gong)(gong)司(si)(si)并(bing)(bing)(bing)購的(de)(de)持(chi)續(xu)關注，預計創(chuang)新藥(yao)械行(xing)業(ye)(ye)中(zhong)的(de)(de)并(bing)(bing)(bing)購將更為(wei)頻(pin)繁。（中(zhong)國(guo)證券(quan)報）